{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:05:08Z","timestamp":1783037108012,"version":"3.54.6"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,6,17]]},"abstract":"<jats:p>\n            In a mouse urinary tract infection model, omadacycline (OMC) was comparable to gentamicin and better than ciprofloxacin (CIP) against a tetracycline-susceptible (TET-S), CIP-resistant (CIP-R)\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            strain. Gentamicin showed better efficacy than OMC against a TET-R, CIP-R\n            <jats:named-content content-type=\"genus-species\">E. coli<\/jats:named-content>\n            strain, and OMC again showed better efficacy than CIP against this strain. OMC may warrant further study as a potential option for urinary tract infection treatment against CIP-R\n            <jats:named-content content-type=\"genus-species\">E. coli<\/jats:named-content>\n            strains.\n          <\/jats:p>","DOI":"10.1128\/aac.00269-21","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T11:58:37Z","timestamp":1620302317000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Omadacycline against Escherichia coli in a Mouse Urinary Tract Infection Model"],"prefix":"10.1128","volume":"65","author":[{"given":"Kavindra V.","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara E.","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"Department of Microbiology and Molecular Genetics, University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2741\/1007"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219832172"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz395"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02488-19"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.01.019"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/367622"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz394"},{"key":"e_1_3_2_10_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2021","unstructured":"CLSI. 2021. Performance standards for antimicrobial susceptibility testing, 31st ed. CLSI M100-ED 31. Clinical and Laboratory Standards Institute, Annapolis Junction, MD.","edition":"31"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06102-11"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/517524"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a118408"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02434-16"},{"key":"e_1_3_2_15_2","unstructured":"FDA. 2020. FDA identified breakpoints for omadacycline. https:\/\/www.fda.gov\/drugs\/development-resources\/omadacycline-injection-and-oral-products. Accessed 30 March 2021."},{"key":"e_1_3_2_16_2","unstructured":"McKenney D Quinn JM Jackson CL Guilmet JL Landry JA Tanaka SK Cannon EP. 2003. Evaluation of PTK 0796 in experimental models of infections caused by gram-positive and gram-negative pathogens abstr 2627. 43rd Intersci Congr Antimicrob Agents Chemother (ICAAC) Chicago IL. American Society for Microbiology Washington DC."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1665022"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit052"},{"key":"e_1_3_2_19_2","unstructured":"Tetraphase Pharmaceuticals. 2018. Tetraphase announces top-line results from IGNITE3 phase 3 clinical trial of eravacycline in complicated urinary tract infections (cUTI). https:\/\/www.globenewswire.com\/news-release\/2018\/02\/13\/1340188\/0\/en\/Tetraphase-Announces-Top-Line-Results-from-IGNITE3-Phase-3-Clinical-Trial-of-Eravacycline-in-Complicated-Urinary-Tract-Infections-cUTI.html."},{"key":"e_1_3_2_20_2","unstructured":"BioSpace. 2019. Paratek announces top line results of phase 2 clinical studies of omadacycline in urinary tract infections. https:\/\/www.biospace.com\/article\/releases\/paratek-announces-top-line-results-of-phase-2-clinical-studies-of-omadacycline-in-urinary-tract-infections\/."},{"key":"e_1_3_2_21_2","unstructured":"ClincalTrials.gov. 2017. Oral omadacycline vs. oral nitrofurantoin for the treatment of cystitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03425396. Accessed March 2021."},{"key":"e_1_3_2_22_2","unstructured":"ClincalTrials.gov. 2018. IV or IV\/PO omadacycline vs. IV\/PO levofloxacin for the treatment of acute pyelonephritis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03757234. Accessed March 2021."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00269-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00269-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:11:46Z","timestamp":1645485106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00269-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6,17]]}},"alternative-id":["10.1128\/AAC.00269-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.00269-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"2021-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00269-21"}}